Cyteir Therapeutics attracts $80m Series C

Cyteir Therapeutics, a developer of next-generation synthetic lethal therapies for cancer, has raised $80 million in Series C financing.

11 February 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles